Sentences with phrase «compounds in clinical trials»

Next, the scientists are interested in testing the grape compounds in clinical trials, and if the human studies are promising, the treatment could become a reality relatively soon.

His work in designing anticancer compounds had led to millions of dollars in funding and multiple patents, as well as two compounds in clinical trials.

«We hope to test this compound in clinical trials,» Ji said.

«We would like to be able to test these compounds in a clinical trial,» Xue says.

Not exact matches

The Chinese government financed nationwide studies into cockroaches» medical value that, after more than two decades of laboratory investigation and clinical trials, had discovered or confirmed dozens of disease - fighting proteins and biochemical compounds with huge potential value in medicine.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Celgene's drugs are currently in over 160 clinical trials, including 42 novel compounds across 60 indications.

A recent study looked at how 244 compounds in 413 clinical trials fared for Alzheimer's disease between 2002 and 2012.

There, he made anticancer compounds, two of which are currently in phase I and phase II clinical trials.

The compound, already proven safe for humans, is undergoing further animal testing in preparation for possible clinical trials in cocaine addicts, the researchers say.

«Our compound is very specific for the target, but the next step is to rigorously establish if it's safe for use in clinical trials,» says Stanford.

The compound is now in phase II clinical trials for diabetic nephropathy and is being explored in other fibrotic diseases.

One of these CDK2 inhibitors, kenpaullone, was more effective than four other compounds that are currently in clinical trials for treating hearing loss.

Several compounds that boost glutamate signalling in the brain have reached early clinical trials, although it is too soon to say if they will pass the larger trials needed to prove their worth.

Bogyo and his associates focused on a compound called ebselen because, in addition to having a strong inhibitory effect, ebselen also has been tested in clinical trials for chemotherapy - related hearing loss and for stroke.

Once a compound has shown its value in these tests, it will begin the process of drug development prior to clinical trials.

One successful compound, named Exel 647, that targets nonsmall - cell lung cancer in previously untreated patients is now in a phase 2 clinical trial.

Some people enrolled in clinical trials with the U.S. National Institutes of Health (NIH) are continuing the use of experimental drugs despite the possibility the compounds have fungal contaminations.

Conventional drug discovery remains a hit - and - miss affair and Hunter believes the 50 percent failure rates seen for experimental compounds in mid - and late - stage clinical trials due to lack of efficacy is unsustainable, forcing a shift to AI.

Julia Lewis, MD (Vanderbilt University School of Medicine) and her colleagues in the Collaborative Study Group conducted a 441 - patient randomized clinical trial to test the potential of a compound called ferric citrate to bind phosphorus, increase iron stores, and reduce the usage of IV iron and ESAs.

Studies in animal models of MS have been a success, and the latest version of the compound is due to start clinical trials in humans by mid-2012.

The compound, already in clinical trials to treat a blood disorder, may also make radiation therapy for cancer safer.

But many such compounds have not been tested for aggression in clinical trials, and most seem ineffective.

«Antiviral compound protects nonhuman primates against Marburg virus: Safety profile also evaluated in phase I clinical trial.»

In order to learn how effective these compounds are, Wilsey says, «they have to do randomized clinical trials, where random people get real terpene and the fake terpene.»

They then soaked tiny collagen sponges (which are made from the same protein found in dentin) in various drugs known to stimulate Wnt signaling, including tideglusib, a compound that has been investigated in clinical trials for its potential to treat Alzheimer's and other neurological disorders.

But the most promising candidates — compounds called vaginal microbicides that thwart the virus at the site of infection — have failed repeatedly in clinical trials.

Established by AllerGen in 2005, the Clinical Investigator Collaborative is globally unique in its ability to undertake early stage clinical trials to evaluate the efficacy of new molecules and compounds that treat inflammation in tClinical Investigator Collaborative is globally unique in its ability to undertake early stage clinical trials to evaluate the efficacy of new molecules and compounds that treat inflammation in tclinical trials to evaluate the efficacy of new molecules and compounds that treat inflammation in the lung.

Watterson and his collaborators have a new National Institutes of Health (NIH) award to further refine the compound so it is metabolically stable and safe for use in humans and develop it to the point of starting a phase 1 clinical trial.

In fact, the researchers point out that phase 1 clinical trials are already underway for compounds targeting this gene in other cancers, meaning that the time needed to apply a similar strategy to mucosal melanoma could be dramatically shorter than if they had to start from scratcIn fact, the researchers point out that phase 1 clinical trials are already underway for compounds targeting this gene in other cancers, meaning that the time needed to apply a similar strategy to mucosal melanoma could be dramatically shorter than if they had to start from scratcin other cancers, meaning that the time needed to apply a similar strategy to mucosal melanoma could be dramatically shorter than if they had to start from scratch.

That collaboration ultimately resulted in clinical trials to assess two compounds for treating cytomegalovirus (CMV) infections, which weaken the immune system.

While this drug shows promise, Berglund said that it might not end up being the compound used in eventual clinical trials.

Millions of new chemical compounds have been tested for their ability to disrupt the growth of M. tuberculosis in the test tube, but discouragingly few are currently in clinical trials.

Several of the compounds are currently in clinical trials to treat cancers like leukemia and myeloma.

Scientists searching for new drugs to fight malaria have identified a number of compounds — some of which are currently in clinical trials to treat cancer — that could add to the anti-malarial arsenal.

The compound is currently in Phase I clinical trials, with Phase II testing slated to begin this year.

Bradner, now at Novartis Institutes for Biomedical Research in Cambridge, Massachusetts, applauds the overall reproducibility effort and says it is «reassuring» that his study passed muster, especially because the compound is already in clinical trials.

Of the many thousands of compounds tested in cells and in animal models each year, only a few will enter clinical trials.

deCODE has in - licensed a compound, DG031, designed to inhibit FLAP, and the company has designed clinical trials to test its effectiveness in reducing key measures of inflammation and in preventing heart attack.

Among the 60 compounds, they found one that previously had been used as an antibiotic and is now in clinical trials for Alzheimer's disease.

PsychoGenics has pioneered the translation of rodent behavioral responses into robust, high throughput, high content phenotyping and its drug discovery platforms, SmartCube ®, NeuroCube ®, and PhenoCube ® have led to shared risk partnerships with major pharma companies such as Sunovion and Roche and resulted in the discovery of several novel compounds now in clinical trials or advanced preclinical development.

These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

Preclinical studies suggested poor bioavailability with a consequent in vivo ineffectiveness for compound 182a [2, 97], while compound 182b entered clinical trials, unfortunately its development was soon suspended [98, 99].

Reykjavik, ICELAND, December 17, 2004 — deCODE genetics (Nasdaq: DCGN) today announced the signing of an agreement under which it will conduct a Phase II information - rich clinical trial next year of a third - party compound as part of a drug development program in asthma.

The research group conducted high throughput screening of over 1000 compounds consisting of existing drugs, including those approved by the Food and Drug Administration (FDA) of USA, Europe or Asia, and drugs under clinical trial, to search for drugs that can regulate the circadian rhythm in mammals.

The company's lead proprietary compound, LMTX ®, has recently completed three Phase 3 clinical trials to evaluate its safety and efficacy in the treatment of Alzheimer's disease and behavioural - variant frontotemporal dementia.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

The identification of effective compounds in vitro allows, after verification in animal models appropriate to consider the establishment of a clinical trial.

However, with few exceptions, the stem cell and regenerative medicine industry has remained inadequately capitalized to carry out large - scale clinical trials independently, and major pharmaceutical firms have tended to show more interest in the use of hiPSCs as a source of large, pure populations of specific somatic cells for use in drug compound screening and toxicology tests, than they have in therapeutic uses of stem cells and their derivatives.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.